Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cord blood-derived mesenchymal stromal cells to maintain remission after immunosuppression withdrawal in pediatric steroid-dependent nephrotic syndrome
2018-001162-42Phase 2Completed
- Sponsor
- IRCCS Fondazione Ca’ Granda Ospedale Maggiore Policlinico
- Start
- Mar 2019
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cord blood-derived mesenchymal stromal cells in nephrosis, sponsored by IRCCS Fondazione Ca’ Granda Ospedale Maggiore Policlinico. Primary endpoint: NS recurrence-free rate at 6 months after immunosuppressive withdrawal. Started Mar 2019; status: completed.
02
Drugs
cord blood-derived mesenchymal stromal cells
03
Conditions
nephrosis
Beyond the preview
Go deeper on 2018-001162-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001162-42.